SCHEMBL25657151

SCHEMBL25657151

CNCC(=O)OCc1cccnc1N(C)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CASP3 P42574 2/20 0.36
▸ SENP8 Q96LD8 2/20 0.36
▸ SENP7 Q9BQF6 2/20 0.36
▸ SENP6 Q9GZR1 2/20 0.36
▸ HTT P42858 4/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ L3MBTL1 Q9Y468 3/20 0.35
▸ GLA P06280 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ LMNA P02545 3/20 0.34
▸ MAPT P10636 2/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ CYP2C19 P33261 2/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ TDP1 Q9NUW8 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23061476 0.84 HTT (0.37) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL25657186 0.84 RAB9A (0.37) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL17485425 0.84 RAB9A (0.39) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL24496166 0.83 KCNH2 (0.36) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL22651406 0.83 ELANE (0.38) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL22650959 0.82 NPC1 (0.36) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL24604432 0.81 NPC1 (0.35) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL22651234 0.81 RAB9A (0.38) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL23084630 0.80 NPC1 (0.35) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL23698605 0.80 HTT (0.35) NPC1RAB9ASMN1; SMN2CASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151024-A1 STING AGONISTIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-18 — — US disclosed
US-20230141284-A1 CANCER THERAPEUTIC METHOD ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-11 — — US disclosed
US-20230141284-A1 CANCER THERAPEUTIC METHOD ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141284-A1 CANCER THERAPEUTIC METHOD STING1, CGAS, IFNAR1 NPC1 2553/4885RAB9A 2212/4885SMN1; SMN2 4420/4885
US-20230151024-A1 STING AGONISTIC COMPOUND STING1, CGAS, TLR1 NPC1 1311/4885RAB9A 2718/4885SMN1; SMN2 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback